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Abstract
DNA methyltransferase 1 (DNMT1) is the enzyme most responsible for epigenetic modification of human DNA and the
intended target of approved cancer drugs such as 5-aza-cytidine and 5-aza-29-deoxycytidine. 5-aza nucleosides have
complex mechanisms of action that require incorporation into DNA, and covalent trapping and proteolysis of DNMT
isozymes. Direct DNMT inhibitors are needed to refine understanding of the role of specific DNMT isozymes in cancer
etiology and, potentially, to improve cancer prevention and treatment. Here, we developed a high throughput pipeline for
identification of direct DNMT1 inhibitors. The components of this screen include an activated form of DNMT1, a restriction
enzyme-coupled fluorigenic assay performed in 384 well plates with a z-factor of 0.66, a counter screen against the
restriction enzyme, a screen to eliminate DNA intercalators, and a differential scanning fluorimetry assay to validate direct
binders. Using the Microsource Spectrum collection of 2320 compounds, this screen identified nine compounds with dose
responses ranging from 300 nM to 11 mM, representing at least two different pharmacophores with DNMT1 inhibitory
activity. Seven of nine inhibitors identified exhibited two to four-fold selectivity for DNMT1 versus DNMT3A.
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Introduction
In eukaryotes, the most common DNA modification is
methylation of the 5 carbon of cytosines, predominately in CpG
dinucleotides. Methylation patterns are established and main-
tained by a family of enzymes known as DNA methyltransferases
(DNMTs). De novo methyltransferases, DNMT3A and DNMT3B,
establish methylation patterns during germ cell and embryonic
development. These proteins are aided by DNMT3L, a catalyt-
ically inactive isoform that forms complexes with DNMT3A and
DNMT3B [1]. Methylation patterns are primarily maintained by
DNMT1, which is the most abundant DNMT and possesses
specificity for methylation of hemimethylated DNA [2,3]. DNA
methylation is an important epigenetic mark associated with gene
repression that plays a critical role in development and differen-
tiation, genome stability, genomic imprinting, X-chromosome
inactivation and silencing of retrotransposons [4]. Aberrant DNA
methylation has been linked to several diseases including
schizophrenia [5], Rett Syndrome [6], autoimmune diseases [6–
8], hereditary sensory neuropathy, dementia and hearing loss [9],
and cancer [10,11]. In malignancies, normal methylation patterns
are disrupted such that global cytosine DNA methylation is
reduced, while the regulatory regions of many tumor suppression
genes are hypermethylated, resulting in gene silencing [12].
Though genetic changes associated with cancer cannot be
corrected, epigenetic changes, such as DNA methylation, are
dynamic and amenable to reversal. Epigenetic reprogramming,
accomplished by pharmacological targeting of DNMTs, could be
expected to result in restoration of a more differentiated and less
proliferative state, and regression to a lower degree of drug
resistance [13].
The link between the DNMT isozyme DNMT1 and cancer
initiation and progression is well established. DNMT1 activity is
increased in a variety of malignancies. Several common oncogenic
pathways result in the overexpression of DNMT1, either via
transcriptional or post-translational mechanisms [14–17] and
targeting the DNMT1 isozyme for cancer therapy has been
validated genetically. For example, lowering the level of DNMT1
with a Dnmt1 null over Dnmt1 reduced activity genotype protects
against tumor formation in Apc(Min) mice [18]. In addition,
knocking down DNMT1 with antisense oligonucleotides inhibits
neoplasia in cell culture and in mouse tumor models [19,20].
Though genetic experiments can easily target specific DNMT
isozymes, this has not been accomplished by pharmacological
agents. Discovery of DNMT1 isozyme specific inhibitors could be
of great importance as DNMT3A is inactivated in a high
proportion of malignancies such as acute myeloid leukemia [21].
Two distinct classes of demethylating agents have been
reported. Nucleoside inhibitors such as 5-aza-cytidine and 5-aza-
29-deoxycytidine are FDA-approved prodrugs for treatment of
myelodysplastic syndrome [22]. However, these compounds have
complicated mechanisms of action that require their incorporation
into DNA. Once incorporated, 5-aza nucleotides act as suicide
inhibitors, which trap DNMT isozymes in covalent DNA-protein
complexes that are cleared by proteolysis and DNA repair, which
contributes to the mechanism of action. 5-aza nucleosides are
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incorporated nonspecifically into the genome, i.e., not specifically
at CpG dinucleotides. Because 5-aza-cytidine metabolism includes
formation of 5-aza-CTP and incorporation into RNA, significant
toxicity can occur [22,23]. The second class of reported
demethylating agents are non-nucleoside inhibitors. This class
contains compounds of broad chemical diversity, many of which
have other known targets [24]. These agents include compounds
that directly inhibit all DNMT isozymes, such as the SAM-
competitive inhibitor SGI-1027 [25], and other compounds
lacking in direct experimental evidence for a mechanism of
inhibition. The cytotoxicity and lack of specificity of known DNA
demethylating agents suggests a need for new DNMT inhibitors.
Thus, we set out to discover novel direct inhibitors of DNMT1
enzyme activity.
Two factors that have delayed discovery of DNMT1 enzyme
inhibitors are the intrinsic low activity of the enzyme and the
laborious nature of traditional DNA methylation assays utilized to
examine DNMT activity [26]. We recently solved both problems
by discovering that the replication foci targeting sequence (RFTS)
domain is an intrinsic, DNA-competitive inhibitor of DNMT1
enzyme activity and by employing a fluorigenic assay with
outstanding signal-to-noise [27]. Two other high throughput
screening (HTS)-compatible assays have been recently reported
[28,29]. Both assays were used to screen for inhibitors of the de novo
methyltransferase DNMT3A. The scintillation proximity assay
was also used to screen DNMT3A hits against DNMT1 [29].
Here, we report optimization of an endonuclease-coupled
DNMT1 assay to screen a 2320 compound library for small
molecules that inhibit DNMT1 enzyme activity. Following
validation of initial HTS hits, candidate inhibitors were screened
for direct binding of DNMT1 in the absence of substrates using
differential scanning fluorimetry (DSF). The pipeline described
here resulted in discovery of nine previously unreported, direct
DNMT1 inhibitors without activity as DNA intercalators. Seven of
nine compounds exhibit modest selectivity for DNMT1 versus
inhibition of DNMT3A/DNMT3L.
Materials and Methods
DNMT Expression and Purification
Truncated forms of human DNMT1 (RFTS-lacking DNMT1,
amino acids 621–1616 and RFTS-containing DNMT1, amino
acids 351–1616) were expressed and purified as previously
reported [27]. Full-length human DNMT3L was expressed and
purified as previously described [30]. The catalytic domain of
human DNMT3A (CD-DNMT3A; amino acids 611–912) was
expressed as an N-terminally his-tagged protein in Rosetta
2(DE3)pLysS competent cells (Novagen). Cells were grown to an
optical density of ,0.5 and then cooled to 18uC. Protein
expression was induced with 0.5 mM IPTG and cultures were
grown at 18uC for 16 hours. Following cell lysis, protein was
purified via metal affinity using Ni-NTA resin (GE Life Sciences).
Bound protein was eluted with 50 mM HEPES pH 8, 300 mM
NaCl, 400 mM imidazole, 4 mM b-mercaptoethanol, 5% glycer-
ol. Eluted protein was buffer exchanged into 20 mM HEPES
pH 8, 0.2 M NaCl, 2 mM DTT, 5% glycerol and further purified
using a Heparin HP Hi-Trap column (GE Life Sciences). Bound
protein was eluted using a linear gradient from 0.2 to 1.25 M
NaCl. Eluted CD-DNMT3A was concentrated and stored at
280uC in 50% glycerol. The CD-DNMT3ANDNMT3L complex
was prepared by overnight 1:1 molar incubation at 4uC in 10 mM
Tris pH 7.5, 300 mM NaCl, 2 mM DTT. All proteins were
quantified using A280 and calculated extinction coefficients.
Endonuclease-Coupled DNA Methylation Assay
DNMT activity was measured at 37uC using a fluorogenic DNA
methylation assay [27]. In short, a hemi-methylated hairpin
oligonucleotide with a 59 fluorophore and a 39 quencher is
methylated by addition of a DNMT and the methyl-donating co-
factor, S-adenosyl methionine (SAM, HPLC-purified from Sigma).
The fully methylated product is a substrate for the restriction
endonuclease GlaI (Sibenzyme), which cleaves the oligonucleotide,
releasing the fluorophore from the quencher and generating
fluorescence. The oligonucleotide substrate (59-FAM–
CCTATGCGmCATCAGTTTTCTGATGmCGmCATAGG-
39-Iowa Black, in which mC denotes 5-methyldeoxycytidylate
residues), termed 8006, was synthesized by Integrated DNA
Technologies, Coralville, IA. 96 well assays were performed in Co-
Star black half-area plates and read in a Biotek Synergy Neo plate
reader. 384 well assays were performed in Nunc flat-bottomed
black plates and read in a PerkinElmer EnVision plate reader.
FAM fluorescence was measured using excitation and emission
wavelengths of 485 nm and 520 nm, respectively.
High-Throughput Assay and Hit Validation
HTS against the Spectrum compound collection (Microsource,
Gaylordsville, CT) was performed in eight 384 well plates. Using a
Multiflo dispenser (Biotek), 75 ml of assay buffer (10.8 mM Tris-
HCl pH 7.5, 1.08 mM MgCl2, 1.08 mM DTT, 108 mM potas-
sium glutamate, 0.108 mg/ml BSA, 10.8 mM SAM, 21.6 nM
oligonucleotide 8006, 5.4% glycerol) was dispensed into each well.
1 ml of each compound at 880 mM in DMSO (columns 3–22) or
DMSO (columns 1, 2, 23 and 24) was added to assay plates using a
Microlab Star liquid handling robot (Hamilton) and the plate was
incubated at 37uC for 10 minutes. Following this warming step,
5 ml enzyme solution (either a DNMT1-containing solution of
20 mM Tris-HCl, pH 7.5, 300 mM NaCl, 2 mM DTT, 49 nM
DNMT1 (amino acids 621–1616), 0.08 U/ml GlaI, 30% glycerol
to columns 2–23 or a GlaI control solution of 20 mM Tris-HCl,
pH 7.5, 300 mM NaCl, 2 mM DTT, 0.08 U/ml GlaI, 30%
glycerol to columns 1 and 24) was added and the plate was again
incubated at 37uC for 25 minutes. The final composition of the
HTS assay was 11.2 mM Tris-HCl, pH 7.5, 1 mM MgCl2,
1.12 mM DTT, 100 mM potassium glutamate, 18.5 mM NaCl,
0.1 mg/ml BSA, 10 mM SAM, 20 nM oligonucleotide 8006,
6.85% glycerol, 0.4 U GlaI, 3 nM DNMT1, 10.9 mM test
compound, 1.23% DMSO. Each 384 well plate contained two
columns of negative (n) and positive (p) controls for inhibitor
activity. Columns 2 and 23 were the n controls with DMSO
without test compound. Columns 1 and 24 were the p controls
without DNMT1. Thus, 320 compounds were assayed per 384
well plate in columns 3–22.
Assay performance was assessed across the screen using the
following parameters: the signal-to-noise (S/N) ratio = (mn2mp)/
SDn, the signal-to-background (S/B) ratio = mn/mp, and the Z’-
factor = 12 3*(SDp +3SDn)/(mn2mp), in which SDp and SDn are
standard deviations, and mn and mp are means of the n and p
control wells of each plate [31].
Data across the screen were normalized to the p (0% DNMT1
activity) and n (100% DNMT1 activity) controls on each plate.
Compounds that resulted in at least a 5 SD reduction in observed
DNMT1 activity (,41%) were considered potential hits and were
re-examined. Validation assays (81 ml total volume, identical
buffer conditions to those used in the HTS screen) were performed
in triplicate in 96 well plates with FAM fluorescence measured
over the course of 1 hour. A control containing GlaI in the absence
of DNMT1 was subtracted from each assay condition. Corrected
DNMT1-Targeted HTS Pipeline
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assay traces were plotted and compared to DMSO-containing
control traces in Prism (GraphPad Software, Inc).
Differential Scanning Fluorimetry (DSF) Assay
DSF [32] was used to assess the ability of the validated
inhibitors to bind directly to DNMT1 in the absence of DNA and
SAM and alter the observed melting temperature (Tm). Assays
(25 ml) were conducted in triplicate in a Bio-Rad C1000 Thermal
Cycler – CFX Real-Time System using the FRET channel and
contained 50 mM HEPES pH 7.5, 150 mM NaCl, 2 mM
DNMT1 (amino acids 621–1616), 5X Sypro Orange (Invitrogen
Molecular Probes), 100 mM compound, and 1% DMSO. A
DMSO control assay in the absence of compounds was also
examined. Temperature was increased from 25 to 95uC by 0.5uC
per minute. Fluorescence traces were exported and analyzed by
fitting to the Boltzmann equation in Prism to determine the Tm.
GlaI Counterscreen
GlaI inhibitors were identified and excluded using a fluores-
cence-based assay. Duplicate assays (80 ml) were conducted in 96
well plates. Assays contained 10 mM Tris-HCl pH 7.5, 100 mM
potassium glutamate, 1 mM MgCl2, 1 mM DTT, 0.1 mg/mL
BSA, 5% glycerol, 5 nM oligonucleotide 8007 (59-FAM-
CCTATGmCGmCATCAGTTTTCTGATGmCGmCATAGG-
39-Iowa Black, where mC denotes 5-methyldeoxycytidylate
residues, Integrated DNA Technologies, Coralville, IA), 0.2 U
GlaI, 11 mM test compound and 1.2% DMSO. Reactions were
initiated by the addition of GlaI. Cleavage of the oligonucleotide
releases the 59 FAM fluorophore from the 39 Iowa Black quencher
and generates fluorescence. A control reaction in the absence of
GlaI was subtracted from each assay condition to account for
background fluorescence of the internally quenched substrate.
Corrected time courses were fitted in Prism.
Detergent Test
The effect of detergent on observed DNMT1 inhibition was
examined using the endonuclease-coupled DNA methylation
assay. Triplicate assays (81 ml) containing 10 mM SAM, 20 nM
oligonucleotide 8006, 0.4 U GlaI, 2 nM DNMT1 (amino acids
621–1616), 5 mM inhibitor and 1.21% DMSO in the presence and
absence of 0.01% Triton X-100 were conducted in 96 well plates
in a BioTek Neo plate reader at 37uC. A control containing GlaI
in the absence of DNMT1 was subtracted from each assay
condition. Corrected assay traces were fitted in Prism.
DNA Intercalation Assay
DNA intercalation was assessed by examining the ability of the
compounds to displace ethidium bromide from calf thymus DNA
(ctDNA; Sigma). Duplicate assays (100 ml) were conducted in black
96 well plates and contained 15 mg/ml ctDNA, 1.5 mM ethidium
bromide and 10 mM compound in methylation assay buffer.
DMSO was used as a negative control and daunorubicin (Sigma)
was used as a positive control. Fluorescence was measured using
excitation and emission wavelengths of 320 nm and 600 nm,
respectively.
Concentration-Dependence Experiments
IC50 values for each validated direct inhibitor were determined
under identical assay conditions (10 mM SAM and 20 nM
oligonucleotide 8006) using the endonuclease-coupled DNA
methylation assay in triplicate (80 ml) in a 96 well format. Assays
contained 0.8 U GlaI, 2 nM DNMT1 (amino acids 621–1616)
and 0.94% DMSO with inhibitor concentration varied from 0 to
10 mM. FAM fluorescence was measured in a Biotek Neo plate
reader over the course of 45 minutes. A control containing GlaI in
the absence of DNMT1 was subtracted from each assay condition.
Corrected assay traces were fitted in Prism and percent activity
was determined by comparing to a DMSO containing control.
IC50 values were determined by fitting the percent activity data
using a unity Hill slope in Prism.
Compound Selectivity
After identifying direct inhibitors of DNMT1 lacking the RFTS
domain, inhibitor selectivity was assessed by examining inhibition
of RFTS-containing DNMT1 (amino acids 351–1616), CD-
DNMT3A/DNMT3L complex, and the bacterial cytosine meth-
yltransferase from M. SssI (New England Biolabs) using the
endonuclease-coupled DNA methylation assay. Triplicate assays
(100 ml) containing 0.25 mM SAM, 0.2 mM oligonucleotide 8006,
0.8 U GlaI, 20 nM methyltransferase, 20 mM inhibitor and 1%
DMSO were conducted in 96 well plates. Following enzyme
addition, assay plates were incubated at 37uC for 75 min and
fluorescence was measured in a BioTek Neo plate reader. A
control containing only GlaI was subtracted from each assay. SGI-
1027, a non-selective DNMT inhibitor [25], was used as a positive
control and 5-aza-cytidine (Sigma) was used as a negative control.
Percent activity was determined by comparing product formation
to a DMSO containing control assay.
Results
High Throughput Screening
Targeting epigenetic changes is a promising cancer therapy
strategy as aberrant DNA methylation is closely related to
initiation and progression of many cancers [12]. The link between
DNMT1 hyperactivity and cancer is well established [12,33],
making DNMT1 an important cancer drug target. For this reason,
we set out to develop a pipeline to discover novel, direct small
molecule inhibitors of DNMT1 activity. The sine qua non for small
molecule screening is a robust assay. We previously refined an
in vitro assay for DNMT1 that couples DNA methylation to
fluorescence generation using the restriction endonuclease GlaI
[27], allowing for an activity assay that is exquisitely sensitive. This
assay utilizes a hemimethylated hairpin DNA substrate with a 59-
FAM fluorophore and a 39 quencher. The fully methylated
product oligonucleotide is a substrate for the restriction endonu-
clease GlaI. Cleavage of the product DNA releases the fluorophore
from the quencher and generates fluorescence. Using this
endonuclease-coupled DNA methylation assay, we showed that
an N-terminal deletion of sequences up to and including the RFTS
domain, the first 620 amino acids, results in an enzyme that is 640-
fold more active [27]. This de-repressed form of DNMT1, with a
kcat/Km of ,106 M21 s21 [27], has sufficient catalytic power to
allow for facile identification of inhibitors using the fluorogenic
assay.
To determine if the endonuclease-coupled DNA methylation
assay is suitable for HTS, we first evaluated the effect of DMSO on
the observed activity of the de-repressed form of DNMT1 (amino
acids 621–1616). The presence of up to 5% DMSO, the highest
value tested, has no effect on DNMT1 activity (Fig. S1), indicating
that DMSO does not retard DNMT1 or inhibit the DNA
methylation detection system. Next, to increase throughput, we
wished to ensure the assay could be miniaturized to 384 well
plates. Range-finding experiments at a variety of substrate
concentrations, enzyme amounts, volumes and time were
performed. Conditions were chosen in which the DNA substrate
is at 20 nM, 10–20 times Km,DNA [27,34], to bias against selection
DNMT1-Targeted HTS Pipeline
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of DNA-competitive inhibitors, SAM is at 10 mM, 5 times Km,SAM
[34], to permit identification of SAM competitors, and reactions
were scored 25 minutes post enzyme addition. Using DNMT1
plus GlaI endonuclease to represent 100% DNMT1 activity, and
GlaI in the absence of DNMT1 to represent 0% DNMT1 activity,
a Z’-factor of 0.66 was obtained for the miniaturized DNA
methylation assay (Fig. 1). The S/B ratio (4.2) and S/N ratio (12.9)
indicate that the assay is robust for HTS.
The miniaturized endonuclease-coupled DNA methylation
assay was used to screen the Spectrum compound collection for
inhibitors of DNMT1 activity. These 2320 compounds provide a
wide-range of biological activities and structural diversity. The
collection contains drug and drug-like synthetic compounds as well
as natural products. The quality of the assay was assessed by
determining the S/B ratio, S/N ratio and Z’-factor of each of the
eight 384 well plates in the screen (Fig. 2). The average values
across the screen are similar to the values obtained in the control
assay. With average S/B ratio, S/N ratio and Z’-factor values of
4.660.4, 8.861.4 and 0.5260.06 respectively (Fig. 2), screening of
the Spectrum collection was successful. Compounds were picked
as hits if resulting activities were greater than 5 standard deviations
below the mean of the negative controls (Fig. 3). Of 2320
compounds examined, 57 (2.5%) were primary hits. Each of the 57
primary hits was re-tested in triplicate for DNMT1 inhibition
using the endonuclease-coupled DNA methylation assay. For
validation, time-dependent reactions traces for each candidate
inhibitor and a DMSO control reaction were collected. 11 of 57
primary hits failed to inhibit DNMT1 (Table S1), whereas 46
compounds inhibited product formation by at least 40% (Table
S1), giving an apparent hit rate of ,2%.
Identification of Direct DNMT1 Inhibitors
Direct DNMT1 inhibitors have the potential to be useful
molecular probes and possibly leads for drug development. To
ensure that the inhibitory effect exhibited by the validated HTS
hits stems from a direct interaction with DNMT1, we employed
DSF [32] to determine the observed melting temperature (Tm) of
DNMT1 in the presence of each candidate inhibitor. Compounds
that directly interact with target proteins in the absence of
substrates frequently stabilize against thermal denaturation and
shift the observed Tm to right. Thus, comparing the Tm observed in
the presence of a small molecule to that observed in the presence
of DMSO should allow for detection of direct inhibitors. Of 46
compounds tested, five could not be assayed by DSF. These
compounds either strongly quenched the Sypro Orange fluores-
cence signal or were fluorescent and interfered with the assay. The
majority of compounds assayed had no significant effect of the
observed melting temperature (Table S2). Addition of 27 of the 41
successfully assayed compounds resulted in Tm values within
,0.5uC of that observed for DNMT1 alone. However, addition of
12 compounds shifted the observed Tm to the right by at least
0.9uC (Table S2), indicating that the compounds make a
stabilizing interaction with the protein.
Though 12 compounds bind DNMT1 directly as indicated by
DSF, we aimed to eliminate those compounds that interfere with
an aspect of the endonuclease-coupled DNA methylation assay,
making it difficult to determine their effect on DNMT1 activity.
To assess the possibility that the small molecules inhibit GlaI or
quench fluorescence of the 59-FAM product, the 12 candidate
DNMT1 inhibitors were counterscreened against GlaI in a
fluorogenic assay using a fully CpG-methylated hairpin DNA
substrate (Fig. S2). Addition of 10 of the 12 compounds resulted in
activities $79% of that observed with DMSO alone (Table S3).
However, addition of two compounds resulted in observed
activities of ,40%. Due to their interference with the coupling
reaction used in the DNA methylation assay, these compounds
were not considered DNMT1 inhibitors.
To further investigate inhibition of DNMT1 by the direct-
binding compounds, a detergent test was performed. Inhibition of
each compound was investigated in the presence and absence of
0.01% Triton X-100 to eliminate promiscuous molecules that
inhibit by nonspecific aggregation of protein targets [35]. The
presence of Triton X-100 did not reduce the inhibition observed
for 9 compounds (Table S4). However, observed inhibition was
almost completely lost in the presence of detergent for one
candidate inhibitor. For this reason, this compound was excluded
from further study.
Finally, while the compounds shift the observed Tm of DNMT1
in the absence of DNA, indicating that they directly interact with
the enzyme, we sought to ensure that the mechanisms of inhibition
of these compounds are not due to DNA intercalation. To address
this possibility, the compounds were added to a DNA-ethidium
bromide mixture. If the compounds compete with ethidium
bromide and intercalate into DNA, the fluorescence intensity of
ethidium bromide will decrease. None of the validated direct hits
were capable of decreasing ethidium bromide fluorescence,
indicating that they are not strong DNA intercalators (Table S5).
In comparison, addition of daunorubicin, a known DNA
intercalator [36], significantly reduced fluorescence in this assay.
Overall, the high throughput pipeline described resulted in the
discovery of 9 direct inhibitors of DNMT1 enzymatic activity
(Fig. 4) from 2320 compounds in the Spectrum collection.
Concentration-Dependence of Inhibition
To gauge the potency of the 9 resulting compounds, the
concentration-dependence of inhibition was investigated using the
endonuclease-coupled DNA methylation assay. Under identical
conditions (10 mM SAM and 20 nM hairpin oligonucleotide
8006), each inhibitor was varied from 100 nM to 10 mM. The
Figure 1. Z’-factor determination of HTS assay in 384 well
plates. In a 384 well plate, 192 wells were used as negative controls
(N), DMSO in the presence of DNMT1 and GlaI, and 192 wells were used
as positive controls (&), DMSO in the presence of GlaI alone. The solid
line represents the mean value of the positive and negative controls,
267 and 1133 respectively. The dashed lines represent 3 standard
deviations above and below the averages. The Z’-factor calculated from
this data is 0.66.
doi:10.1371/journal.pone.0078752.g001
DNMT1-Targeted HTS Pipeline
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percent activity observed at each condition was determined by
comparing to an uninhibited DMSO-containing control reaction.
The 9 compounds examined exhibited IC50 values ranging from
300 nM to 11 mM (Fig. 5 and Table 1).
Inhibitor Selectivity
Most characterized DNMT inhibitors are not isozyme-selective.
With three catalytically active DNMTs in humans and the finding
that DNMT3A acts as a tumor suppressor [21], isozyme selectivity
of DNMT inhibitors is important. The compounds discovered
using this high throughput pipeline are direct inhibitors of the
truncated and activated form of DNMT1 (amino acids 621–1616)
in vitro. To investigate selectivity for inhibition of methylation of
oligonucleotide 8006, three methyltransferases was examined:
RFTS-containing DNMT1 (amino acids 351–1616), the CD-
DNMT3A/DNMT3L complex, and the bacterial methyltransfer-
ase from M.SssI. SGI-1027 was used as a positive control because
it is has been shown to inhibit each enzyme [25]. 5-aza-cytidine
was used as a negative control; this nucleoside inhibitor must be
incorporated into DNA to exert inhibitory effects on DNMTs.
The percent activity observed for each enzyme was determined by
comparing to an uninhibited DMSO-containing control assay. As
expected, SGI-1027 inhibited the activity of all DNMTs tested,
Figure 2. Quality control of Spectrum HTS experiment. A) The S/N ratio (&) and S/B ratio (N) were calculated from control wells on each of
the 8 384 well plates in the screen. Average values across the screen are represented by a solid line. The average S/N ratio was 8.861.4. The average
S/B ratio was 4.660.4. B) The Z’-factor of each plate was calculated using the positive and negative controls on the plate. The average across the
screen, represented by a solid line, was 0.5260.06.
doi:10.1371/journal.pone.0078752.g002
DNMT1-Targeted HTS Pipeline
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while addition of 5-aza-cytidine did not inhibit any enzyme
examined (Table 2). Seven of nine compounds discovered in this
HTS campaign showed some selectivity. Whereas triclosan (cmpd
13) and alizarin (cmpd 26) inhibited each enzyme to a similar
degree, the other seven compounds either showed a preference for
inhibition of DNMT1 or for inhibition of both DNMT1 and
M.SssI, but not DNMT3A/DNMT3L. The observed selectivity
for DNMT1 over DNMT3A/DNMT3L in this assay was two to
four-fold.
Figure 3. HTS screen of the Spectrum library. Raw fluorescence data from the Spectrum screen were normalized to the assay controls on each
plate. The normalized data are shown as circles with each assay plate being a different color. The solid lines represent the average value of the
positive (m) and negative (.) controls. The dashed black lines represent one standard deviation from the positive and negative controls. The red
dashed line represents 5 standard deviations below the average negative control. Compounds below this cutoff were considered primary hits. 57 of
the 2320 compounds were identified as hits.
doi:10.1371/journal.pone.0078752.g003
Figure 4. Structure of identified direct DNMT1 inhibitors. Shown are the 9 identified inhibitors from the Spectrum collection. Compound
numbers correspond to those in all tables and Figure 5. Five compounds contain a quinone-like substructure. Two identified inhibitors are
chlorobenzene compounds.
doi:10.1371/journal.pone.0078752.g004
DNMT1-Targeted HTS Pipeline
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Discussion
Drastic changes to normal DNA methylation patterns occur in
malignancy. The genome typically becomes globally hypomethy-
lated with regional hypermethylation and gene silencing of tumor
suppressor genes [12]. Targeting these epigenetic changes is a
promising cancer therapy strategy. While modified cytosine
nucleosides, such as 5-aza-cytidine, have been approved to treat
myelodysplastic syndrome, such demethylators are not DNMT
isozyme specific and require incorporation into DNA to exert their
effects [22], suggesting that there is room for improvement in
probe development. Molecular probes targeted at DNMT1
enzyme activity will also be useful in furthering our understanding
of cancer etiology. Such molecules can be used to determine the
degree to which DNA methyltransferase enzyme activity as
opposed to DNMT physical interactions is important for gene
silencing and carcinogenesis. Direct inhibitors may also serve as
lead compounds for new cancer therapeutics. Thus, the objective
of developing this high throughput pipeline was to identify novel
direct inhibitors of DNMT1 activity.
The HTS assay described herein is ultrasensitive and requires
only 0.24 pmol of DNMT1 (amino acids 621–1616) per well. In
comparison, a recently described scintillation proximity assay [29]
required almost 0.9 pmol of a similar DNMT1 construct. In
contrast, a different endonuclease-coupled assay that uses biotin to
attach a DNA substrate to a microtiter plate [37] used nearly
17 pmol of full-length DNMT1 per reaction. Our fluorescence-
based DNA methylation assay for DNMT inhibitors requires little
manipulation. The assay can be accomplished by simply adding
test compounds and enzyme to assay solution and reading the
fluorescence generated after a short 37uC incubation. Less than 1
hour is required from plate set-up to final reading, making the
assay simple and scalable.
The initial screen of the Spectrum collection yielded 57 hits that
inhibited DNMT1 activity by at least 5 standard deviations below
the negative control. Following hit validation, 46 compounds
reliably inhibited fluorescence-generation in the endonuclease-
coupled DNA methylation assay. The validated inhibitors were
examined for their ability to bind directly to DNMT1 using DSF
[32]. These assays can be performed in 96 well and 384 well plates
in a real-time PCR machine, permitting HTS for direct inhibition.
Twelve compounds were determined to bind directly with
DNMT1 on account of their ability to shift the observed Tm. A
shift of the observed Tm of at least 0.9uC was used as cutoff for
direct binders. This is in line with previous studies that have shown
changes in Tm of 1–2uC or greater for direct binders of other
Figure 5. Dose-response analysis of the identified direct DNMT1 inhibitors. IC50 values were determined at 20 nM oligonucleotide 8006
and 10 mM SAM for each inhibitor (13– blackN; 22– red&; 24– bluem; 26– green.; 29– orangeN; 33– purple&; 36– pinkm, 40– grey., 51– navyN). Inhibitor concentration was varied from 0.1–10 mM. The percent activity was determined by comparing to an uninhibited DMSO-containing
control. The data were fit using a Hill slope of -1 to obtain IC50 values (Table 1).
doi:10.1371/journal.pone.0078752.g005
Table 1. IC50 values of the 9 compounds identified using the
high throughput pipeline.
Cmpd # Assay Plate Well ID Cmpd ID IC50 (mM)*
13 3 F8 01505465 3.8 (2.4–5.9)
22 4 G5 01504078 0.47 (0.33–0.67)
24 4 J5 01503867 0.40 (0.27–0.60)
26 5 B22 00210850 11 (7.9–15)
29 5 M9 01505786 6.1 (3.4–11)
33 6 A4 01505143 2.9 (1.7–5.0)
36 6 G15 01504080 0.45 (0.33–0.60)
40 6 K10 01505847 2.1 (1.7–2.6)
51 7 O19 00201507 0.33 (0.22–0.51)
*IC50 values obtained by fitting percent activity data shown in Fig. 5 (with 95%
confidence interval).
doi:10.1371/journal.pone.0078752.t001
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targets [32,38,39]. Of the 12 compounds that stabilize DNMT1
against thermal denaturation, 10 were further confirmed as
lacking in GlaI inhibition and 9 were confirmed for their ability
to inhibit in the presence of detergent. These secondary and
confirmatory assays reduced the number of direct DNMT1
inhibitors to nine, 0.39% of all compounds screened.
All 9 inhibitors discovered using this high throughput pipeline
show concentration-dependent inhibition of DNMT1 activity
in vitro, with IC50 values ranging from 0.3–11 mM (Fig. 5 and
Table 1). The majority of compounds identified are polycyclic
aromatics (Fig. 4). Though many such compounds are DNA
intercalators, these molecules did not inhibit GlaI cleavage of the
DNMT1 product oligonucleotide, they shifted the melting
temperature of DNMT1 in DSF assays that included no DNA,
and they failed to compete with ethidium bromide in DNA
intercalation assays. Compounds similar in structure to our
identified compounds, such as nitroflavones and dichlone [28],
were recently reported to inhibit DNMT3A, suggesting that
polycyclic aromatics may profitably be screened for inhibition of
DNMT isozymes.
Our high throughput pipeline used a truncated form of
DNMT1 (amino acids 621–1616) due to its increased in vitro
activity [27]. To examine the ability of the identified compounds
to inhibit full-length DNMT1, we tested them against RFTS-
containing DNMT1 (amino acids 351–1616), a protein that
behaves similarly to the full-length enzyme in vitro [27]. All of the
identified compounds inhibited the activity of RFTS-containing
DNMT1 (Table 2). To examine isozyme selectivity, the com-
pounds were also screened against the CD-DNMT3A/DNMT3L
complex and the bacterial DNMT from M.SssI. Interestingly, only
alizarin (cmpd 26) and triclosan (cmpd 13) appear to be
nonselective. The seven other compounds identified in the HTS
campaign exhibited two to four-fold selectivity for DNMT1 over
DNMT3A/DNMT3L. While these initial finding are promising,
further work is needed to characterize the new inhibitors.
Structure activity relationship analyses of the inhibitors and
related compounds could reveal more potent and specific
inhibitors.
Of the compounds identified in our screen, five contain
anthracene or anthraquinone-related structures. Laccaic acid A
(LCA, cmpd 40), a highly substituted anthraquinone natural
product, is ,5-fold more potent than alizarin (cmpd 26), an
anthraquinone with only two hydroxyl substituents, suggesting
that substituted anthraquinones represent a novel pharmacophore
for DNMT1 inhibitors. LCA exhibited ,4-fold selectivity for
DNMT1, while alizarin inhibited all DNMTs examined equally.
Further characterization of LCA has shown that it is a DNA-
competitive inhibitor, which reactivates expression of a set of
methylation-silenced genes in MCF-7 breast cancer cells [34]. In
addition, LCA reverses DNMT1-dependent oncogenic transfor-
mation and apoptosis in murine Rgs62/2 mouse embryonic
fibroblasts [40].
This screen also yielded two chlorobenzene compounds,
triclosan (cmpd 13) and triclabendazole (cmpd 29), with similar
potencies against the activated form of DNMT1. A recent study
has shown that treatment with triclosan reduced the levels of DNA
methylation in HepG2 cells [41]. Triclabendazole but not
triclosan exhibited selectivity for DNMT1 versus DNMT3A/
DNMT3L.
The high throughput pipeline described in this study was used
successfully to identify direct inhibitors of DNMT activity in vitro
from a small chemical library. Whereas alizarin and triclosan
appear to be nonspecific DNMT inhibitors, seven other
compounds appear to be at least partially selective for DNMT1
over DNMT3A/DNMT3L. Ongoing experiments are designed to
determine their mechanisms of inhibition, cellular availability and
cellular isozyme specificity. Structure activity relationship data and
co-crystallization studies are expected to aid in further defining
DNMT1 pharmacophores. The pipeline described herein can be
used to screen larger and more diverse libraries of chemical matter
to discover additional tool compounds and leads for clinical
DNMT1 inhibition.
Supporting Information
Figure S1 DMSO tolerance of DNMT1. DNMT1 activity
was assayed at 20 nM oligonucleotide 8006 and 10 mM SAM
using 2 nM DNMT1. DMSO concentration was varied from 0–
5% (0– filled circles; 0.5– filled squares; 1– filled triangles; 2– filled
diamonds; 3– open circles; 4– open squares; 5– open triangles).
Addition of DMSO has little effect on the observed activity of
DNMT1. RFU, relative fluorescence unit.
(TIF)
Figure S2 GlaI counterscreen. The effect of each compound
on GlaI activity, the coupling enzyme used in the DNA
methylation assay, was investigated using an internally quenched
Table 2. Percent activity observed using three different DNMTs.
Compound # RFTS-containing Dnmt1 DNMT3A/DNMT3L Complex M.SssI DNMT
13 2568 23610 2564
22 40610 88611 2065
24 N.D.* 49616 49612
26 51610 49612 68611
29 N.D. 11065 1966
33 38613 74613 8669
36 30612 83615 4067
40 2169 80610 82610
51 24611 61612 3667
SGI-1027 N.D. N.D. N.D.
5-aza-cytidine 100611 97610 10065
*N.D. – No detectable activity observed above background.
doi:10.1371/journal.pone.0078752.t002
DNMT1-Targeted HTS Pipeline
PLOS ONE | www.plosone.org 8 November 2013 | Volume 8 | Issue 11 | e78752
hairpin DNA with a fully methylated GCGC site (the cleavage site
of GlaI). GlaI cleavage of the oligonucleotide releases the 59
fluorophore from the 39 quencher, generating fluorescence in real-
time. Shown is the time-dependent cleavage of 5 nM oligonucle-
otide substrate 8007 with 0.2 U of enzyme in the presence of
DMSO (black N) or 11 mM of each compound (13– red N; 22– blue
N; 24– green N; 26– purple N; 29– red&; 30– blue&; 33– green&;
36– purple &; 40– red ¤; 44– blue ¤; 51– green ¤; 53– purple
¤).
(TIF)
Table S1 Validation of the initial 57 hits from the
Spectrum HTS assay. Initial hits were validated as DNMT1
inhibitors using the endonuclease-coupled DNA methylation
assay. Each compound was assayed in triplicate. Shown is the
fluorescence observed following enzyme addition and 25-minute
incubation at 37uC. In addition, observed initial velocities were
determined from GlaI-corrected, time-dependent reaction traces.
The percent activity observed for each inhibitor was determined
by comparing to an uninhibited DMSO-containing control
reaction. 11 compounds failed to inhibit DNMT1 activity in
validation assays.
(DOCX)
Table S2 Melting temperature of DNMT1 determined
using DSF. DSF was used to determine the observed melting
temperature (Tm) of DNMT1 in the presence and absence of
validated hits. 12 compounds stabilized DNMT1 against thermal
denaturation and shifted the observed Tm to right by at least
0.9uC, indicating that they bind directly to DNMT1.
(DOCX)
Table S3 Effect of compounds on GlaI endonuclease
activity. A GlaI counterscreen was performed to determine if the
compounds inhibit the restriction enzyme used in the DNA
methylation assay. Two of the twelve compounds that shifted the
melting temperature of DNMT1 inhibited GlaI activity in this
assay. These compounds were not studied further.
(DOCX)
Table S4 Effect of detergent of inhibition. The percent
activity observed using 5 mM compound in the presence and
absence of 0.01% Triton X-100 was determined. The observed
inhibition with compound 44 was sensitive to detergent. The
inhibitory effect of the other nine compounds examined was not
sensitive to detergent.
(DOCX)
Table S5 DNA Intercalation Assay. DNA intercalation
activities of candidate inhibitors were assessed using an assay
containing calf thymus DNA and ethidium bromide. Ethidium
bromide fluorescence was measured using excitation and emission
wavelengths of 320 and 600 nm, respectively. Compounds that
intercalate DNA decrease the observed fluorescence. Daunorubi-
cin, a known DNA intercalator, was used as a positive control and
significantly reduced the fluorescence signal. None of the
compounds identified in the HTS campaign had a significant
effect on observed fluorescence, indicating that they do not
intercalate into DNA under reaction conditions.
(DOCX)
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